The clinical development of anti-β2M mAbs, both as a monotherapy or in combination with existing MM drugs, such as lenalidomide or BTZ, offers MM patients increased treatment options and improves overall patient outcome. The gene discussed is B2M; the disease is Miyoshi myopathy.